

Valentín Cuervas-Mons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8658703/publications.pdf>

Version: 2024-02-01

158
papers

4,536
citations

109321

35
h-index

118850

62
g-index

172
all docs

172
docs citations

172
times ranked

4775
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid. <i>International Journal of Infectious Diseases</i> , 2022, 116, 339-343.	3.3	8
2	Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. <i>Liver Transplantation</i> , 2022, 28, 1039-1050.	2.4	9
3	Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry. <i>International Journal of Infectious Diseases</i> , 2022, 116, 51-58.	3.3	17
4	Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	2
5	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. <i>Gastroenterology</i> , 2021, 160, 1151-1163.e3.	1.3	130
6	Emergency department frequentation and unscheduled readmissions within the first year after liver transplantation, and their impact on survival. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.3	1
7	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	4.7	32
8	Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain. <i>Medicine (United States)</i> , 2021, 100, e25634.	1.0	19
9	Autoimmune Extrahepatic Disorders in Patients With Autoimmune Liver Disease. <i>Transplantation Proceedings</i> , 2021, 53, 2695-2697.	0.6	1
10	Coronavirus Disease 2019 (COVID-19) in Solid Organ Transplant Recipients: A Case-Control Study. <i>Annals of Transplantation</i> , 2021, 26, e933152.	0.9	3
11	Risk Factors for Clostridioides Difficile Diarrhea In Solid Organ Transplantation Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 2826-2832.	0.6	0
12	COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 724-725.	8.1	72
13	Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. <i>World Journal of Hepatology</i> , 2019, 11, 50-64.	2.0	29
14	Preface. <i>Transplantation Proceedings</i> , 2019, 51, 249.	0.6	0
15	Benefits of hepatitis C cure with antivirals: why test and treat?. <i>Future Microbiology</i> , 2019, 14, 425-435.	2.0	3
16	Mast cell-mediated splanchnic cholestatic inflammation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 561-574.	1.5	7
17	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362.	3.0	16
18	<i>TLR9</i>-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. <i>Biomarkers in Medicine</i> , 2019, 13, 995-1004.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 818-824.	2.0	10
20	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. <i>Transplantation Reviews</i> , 2018, 32, 36-57.	2.9	104
21	Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 532-536.	5.0	22
22	Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. <i>Aids</i> , 2018, 32, 2347-2352.	2.2	55
23	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 2513-2522.	4.7	32
24	Prevalence and progression of chronic kidney disease after a liver transplant: a prospective, real-life, observational, two-year multicenter study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 538-543.	0.3	10
25	Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. <i>Antiviral Therapy</i> , 2017, 22, 307-312.	1.0	50
26	Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. <i>Clinical and Experimental Medicine</i> , 2017, 17, 217-223.	3.6	8
27	Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. <i>Liver Transplantation</i> , 2017, 23, 498-509.	2.4	51
28	HIV type 2 epidemic in Spain. <i>Aids</i> , 2017, 31, 1353-1364.	2.2	18
29	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	3.9	10
30	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017, 31, 1653-1663.	2.2	30
31	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. <i>Transplant International</i> , 2017, 30, 1041-1050.	1.6	6
32	Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2083-2088.	3.0	27
33	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 718-723.	3.7	90
34	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. <i>Transplant Infectious Disease</i> , 2017, 19, e12773.	1.7	26
35	Preface. <i>Transplantation Proceedings</i> , 2017, 49, 749.	0.6	0
36	Impact of ITPA Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2017, 22, 571-575.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Risk Factors for Clostridium Difficile Diarrhea in Patients With Solid Organ Transplantation. Progress in Transplantation, 2016, 26, 231-237.	0.7	15
38	Liver Transplantation for Hepatic Trauma. Transplantation, 2016, 100, 2372-2381.	1.0	24
39	Preface. Transplantation Proceedings, 2016, 48, 2855.	0.6	0
40	Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplantation Proceedings, 2016, 48, 3013-3016.	0.6	3
41	Fecal transplantation for the treatment of relapsing diarrhea associated with Clostridium difficile infection in a liver transplantation patient. Medicina Clínica (English Edition), 2016, 146, e3-e4.	0.2	0
42	Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Genotype 1, after Liver Transplantation: Efficacy and Safety. Journal of Hepatology, 2016, 64, S538-S539.	3.7	0
43	Results of Radiofrequency Ablation in a Cohort of Cirrhotic Patients at Liver Transplantation. Journal of Hepatology, 2016, 64, S698.	3.7	0
44	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. Journal of Hepatology, 2016, 64, S831.	3.7	2
45	Efficacy and Clinical Impact of Daclatasvir-Based Antiviral Therapy in Severe Recurrent Hepatitis C after Liver Transplantation. Results from a Multicenter Spanish Group. Journal of Hepatology, 2016, 64, S547.	3.7	1
46	Rapid Changes in Cholesterol in Chronic Hepatitis C Patients Treated with Antivirals and Potential Impact on Cardiovascular Risk. Journal of Hepatology, 2016, 64, S790-S791.	3.7	3
47	Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience. Journal of Hepatology, 2016, 64, S794-S795.	3.7	1
48	Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. Transplantation Proceedings, 2016, 48, 2515-2518.	0.6	3
49	Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by toll-like receptor 3 polymorphism. Clinical Transplantation, 2016, 30, 810-818.	1.6	8
50	Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. Revista Espanola De Enfermedades Digestivas, 2016, 108, 716-720.	0.3	12
51	P0040 : Long-term cardiovascular mortality after liver transplantation: Analysis of risk factors. Journal of Hepatology, 2015, 62, S306-S307.	3.7	0
52	Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients. Clinical Transplantation, 2015, 29, 667-677.	1.6	15
53	Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transplantation, 2015, 21, 1056-1065.	2.4	35
54	Activity and results of liver transplantation in Spain during 1984-2012. Analysis of the Spanish Liver Transplant Registry. Medicina Clínica (English Edition), 2015, 144, 337-347.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. <i>Transplant Infectious Disease</i> , 2015, 17, 488-492.	1.7	21
56	V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. <i>Cirugía Española</i> , 2015, 93, 619-637.	0.2	3
57	Long-Term Survivors After Pediatric Liver Transplantation Are at Increased Risk for Development of Cardiovascular Disease Events: Analysis of 30 Cases. <i>Transplantation Proceedings</i> , 2014, 46, 3111-3113.	0.6	4
58	TT Genotype of Transforming Growth Factor Beta1+869C/T Is Associated With the Development of Chronic Kidney Disease After Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3108-3110.	0.6	5
59	CC Genotype at rs12979860 of IL28B Is Associated With Lower Risk of New-onset Diabetes After Transplantation in Adult Patients With Liver Transplantation for Hepatitis C Cirrhosis. <i>Transplantation Proceedings</i> , 2014, 46, 3114-3116.	0.6	6
60	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2014, 28, 84-91.	2.9	65
61	P908 EVEROLIMUS TREATMENT IN LIVER TRANSPLANTATION ACCORDING TO CLINICAL PRACTICE: A SPANISH MULTICENTRE COHORT. <i>Journal of Hepatology</i> , 2014, 60, S377-S378.	3.7	0
62	Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. <i>Journal of Hepatology</i> , 2014, 61, 1020-1028.	3.7	90
63	Spontaneous hepatitis C virus clearance in one HIV patient with chronic hepatitis C bearing IL28B-CC alleles and detectable plasma HIV-RNA. <i>Aids</i> , 2014, 28, 2169-2170.	2.2	0
64	Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study. <i>American Journal of Transplantation</i> , 2013, 13, 1734-1745.	4.7	158
65	Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860. <i>Transplantation</i> , 2012, 94, 275-280.	1.0	21
66	Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, 786-794.	6.0	60
67	New concepts and best practices for management of pre- and post-transplantation cancer. <i>Transplantation Reviews</i> , 2012, 26, 261-279.	2.9	82
68	Influence of Infection by <i>Aspergillus</i> in Arterial Complications After Liver Transplantation: Evolution and Results in 670 Transplants. <i>Transplantation Proceedings</i> , 2011, 43, 751-752.	0.6	2
69	Toll-like Receptor 3 L412F Polymorphism May Protect Against Acute Graft Rejection in Adult Patients Undergoing Liver Transplantation for Hepatitis C-Related Cirrhosis. <i>Transplantation Proceedings</i> , 2011, 43, 2224-2226.	0.6	19
70	Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The ReSPECT™ Study. <i>American Journal of Transplantation</i> , 2009, 9, 327-336.	4.7	250
71	A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. <i>Liver Transplantation</i> , 2009, 15, 1542-1552.	2.4	33
72	Breakthrough Rhinocerebral Mucormycosis in a Liver Transplant Patient Receiving Caspofungin. <i>Transplantation Proceedings</i> , 2009, 41, 1972-1975.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Right Adrenal Metastases of Hepatocarcinoma After Liver Transplantation: Case Report and Literature Review. <i>Transplantation Proceedings</i> , 2009, 41, 1067-1069.	0.6	11
74	Hepatitis C Virus Sensitivity to Combined Antiviral Therapy in Liver Transplant Versus Immunocompetent Patients. <i>Transplantation Proceedings</i> , 2009, 41, 2195-2196.	0.6	1
75	Preface. <i>Transplantation Proceedings</i> , 2009, 41, 2293.	0.6	0
76	Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. <i>Liver Transplantation</i> , 2008, 14, 799-805.	2.4	93
77	Donor Infection and Transmission to the Recipient of a Solid Allograft. <i>American Journal of Transplantation</i> , 2008, 8, 2420-2425.	4.7	74
78	Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2008, 46, 20-27.	5.8	71
79	Inmunosupresión en el trasplante hepático. , 2008, , 199-207.		0
80	Trasplante clínico de hepatocitos. , 2008, , 556-560.		0
81	Adrenergic Response of Splanchnic Arteries from Cirrhotic Patients: Role of Nitric Oxide, Prostanoids, and Reactive Oxygen Species. <i>Experimental Biology and Medicine</i> , 2007, 232, 1360-1367.	2.4	5
82	Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. <i>Regulatory Peptides</i> , 2007, 144, 50-55.	1.9	72
83	Endothelium-dependent relaxation of isolated splanchnic arteries from cirrhotic patients: Role of reactive oxygen species. <i>Hepatology Research</i> , 2007, 37, 811-819.	3.4	5
84	Hepatitis C Virus Recurrence After Liver Transplantation: Influence of Immunosuppressive Regimens on Viral Load and Liver Histology. <i>Transplantation Proceedings</i> , 2006, 38, 2499-2501.	0.6	13
85	Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. <i>Transplant International</i> , 2006, 19, 641-648.	1.6	24
86	Hepatitis C Recurrence After Liver Transplantation: Viral and Histologic Response to Full-Dose Peg-Interferon and Ribavirin. <i>American Journal of Transplantation</i> , 2006, 6, 2348-2355.	4.7	123
87	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. <i>Liver Transplantation</i> , 2006, 12, 1464-1472.	2.4	92
88	Therapy of Intractable Pruritus With MARS. <i>Transplantation Proceedings</i> , 2005, 37, 1480-1481.	0.6	25
89	Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 1507-1508.	0.6	19
90	Effectiveness of Pegylated Interferon and Ribavirin in Patients With Liver HCV Cirrhosis. <i>Transplantation Proceedings</i> , 2005, 37, 1482-1483.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Efficacy of Hepatocellular Carcinoma Locoregional Therapies on Patients Waiting for Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1484-1485.	0.6	10
92	Prevalence of Hepatitis C Virus Genotypes in a Spanish Liver Transplant Unit. <i>Transplantation Proceedings</i> , 2005, 37, 1486-1487.	0.6	5
93	Results of Liver Transplantation in Patients With Previous Portosystemic Shunts. <i>Transplantation Proceedings</i> , 2005, 37, 1491-1492.	0.6	6
94	Peginterferon and Ribavirin in Patients With HCV Cirrhosis After Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2207-2208.	0.6	26
95	Five-Year Follow-up of a Trial Comparing Tacrolimus and Cyclosporine Microemulsion in Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1713-1715.	0.6	19
96	Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post-Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 3960-3962.	0.6	34
97	Mycophenolate Mofetil Can Be Used as Monotherapy Late After Liver Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 1650-1655.	4.7	65
98	Infección bacteriana temprana en el paciente con trasplante hepático. <i>Gastroenterología Y Hepatología</i> , 2004, 27, 95-100.	0.5	0
99	Validation and refinement of survival models for liver retransplantation. <i>Hepatology</i> , 2003, 38, 460-469.	7.3	114
100	Late mortality in patients with liver transplantation: causes and risk factors. <i>Transplantation Proceedings</i> , 2003, 35, 707-708.	0.6	5
101	De novo malignancies in liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 709-711.	0.6	21
102	Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 715-717.	0.6	10
103	Recurrence of primary biliary cirrhosis after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 721-722.	0.6	13
104	Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. <i>Transplantation Proceedings</i> , 2003, 35, 1830-1831.	0.6	10
105	Effectiveness of low-dose intramuscular Anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. <i>Transplantation Proceedings</i> , 2003, 35, 1850-1851.	0.6	16
106	Cardiovascular morbidity and obesity in adult liver transplant recipients. <i>Transplantation Proceedings</i> , 2003, 35, 1909-1910.	0.6	41
107	Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. <i>Transplantation Proceedings</i> , 2003, 35, 1907-1908.	0.6	70
108	Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1874-1876.	0.6	34

#	ARTICLE	IF	CITATIONS
109	De novo malignancies and liver transplantation. Transplantation Proceedings, 2003, 35, 1896-1897.	0.6	18
110	Effectiveness and security of mycophenolate mofetil as monotherapy in liver transplantation. Journal of Hepatology, 2003, 38, 45.	3.7	0
111	Influence of immunosuppressive therapy in the incidence of chronic renal failure after liver transplantation. Journal of Hepatology, 2003, 38, 45.	3.7	0
112	Documento de consenso de indicaciones de trasplante hepático. Gastroenterología Y Hepatología, 2003, 26, 355-375.	0.5	12
113	Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplantation Proceedings, 2002, 34, 1511-1513.	0.6	13
114	Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplantation, 2002, 8, 123-131.	2.4	89
115	Chronic renal failure after liver transplantation. Journal of Hepatology, 2002, 36, 191.	3.7	0
116	Recurrence of primary biliary cirrhosis after liver transplantation. Journal of Hepatology, 2002, 36, 194.	3.7	0
117	LIVER TRANSPLANT WITH ORGANS FROM ELDERLY DONORS: SPANISH EXPERIENCE WITH MORE THAN 300 LIVER DONORS OVER 70 YEARS OF AGE. Transplantation, 2002, 73, 1360.	1.0	31
118	PREVALENCE AND IMPACT ON LATE MORTALITY OF CARDIOVASCULAR RISK FACTORS IN AN ADULT LIVER TRANSPLANT POPULATION.. Transplantation, 2000, 69, S406.	1.0	0
119	BASILIXIMAB (SIMULECT®) IS SAFE AND WELL TOLERATED IN ADULT LIVER TRANSPLANTATION AND PROVIDES A LOW RATE OF ACUTE REJECTION.. Transplantation, 2000, 69, S164.	1.0	0
120	THE DEPLETION OF INTRAEPITHELIAL T CELLS FROM INTESTINAL ALLOGRAFTS AMELIORATES THEIR ACCEPTANCE IN MOUSE RECIPIENTS.. Transplantation, 2000, 69, S246.	1.0	0
121	DE NOVO HEPATITIS C DECREASES PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION.. Transplantation, 2000, 69, S314.	1.0	0
122	Trasplante hepático. Medicina, 2000, 8, 606-614.	0.0	0
123	IN VIVO EFFICACY OF A BIOARTIFICIAL LIVER IN IMPROVING SPONTANEOUS RECOVERY FROM FULMINANT HEPATIC FAILURE: A CONTROLLED STUDY IN PIGS1. Transplantation, 2000, 69, 337-344.	1.0	28
124	Visceral Leishmaniasis (Kala-azar) in Solid Organ Transplantation: Report of Five Cases and Review. Clinical Infectious Diseases, 1999, 29, 918-921.	5.8	68
125	Hepatocellular carcinoma: adjuvant chemotherapy postliver transplant. European Journal of Cancer, 1999, 35, S141-S142.	2.8	0
126	Late orthotopic liver retransplant: indications and survival. Transplantation Proceedings, 1999, 31, 511-514.	0.6	9

#	ARTICLE	IF	CITATIONS
127	Incidence and outcome of De Novo malignancies after liver transplantation. Transplantation Proceedings, 1999, 31, 1275-1277.	0.6	44
128	Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. Transplantation Proceedings, 1999, 31, 2461-2463.	0.6	3
129	INFLUENCE OF ANTIVIRAL THERAPY IN THE NATURAL HISTORY OF HEPATITIS B VIRUS RECURRENCE AFTER LIVER TRANSPLANTATION: RETROSPECTIVE STUDY OF 14 CASES. Transplantation, 1999, 67, S201.	1.0	0
130	Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transplant International, 1998, 11, S260-S266.	1.6	14
131	Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A -induced hypertension. Hepatology, 1998, 27, 332-338.	7.3	12
132	Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transplant International, 1998, 11, S260-S266.	1.6	17
133	Infection in Organ-Transplant Recipients. New England Journal of Medicine, 1998, 339, 1244-1246.	27.0	4
134	OUTCOME OF RECURRENT AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. Transplantation, 1998, 65, S25.	1.0	1
135	OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1. Transplantation, 1998, 66, 1645-1650.	1.0	139
136	OUTCOME OF RECURRENT AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. Transplantation, 1998, 65, 101.	1.0	1
137	Biliary tract reconstruction after liver transplantation: With or without T-tube?. Transplantation Proceedings, 1997, 29, 564-565.	0.6	40
138	Induction of peripheral chimerism in an allogenic model of small bowel transplantation with intrathymic inoculation of donor-derived cells. Transplantation Proceedings, 1997, 29, 1067-1069.	0.6	1
139	Oral care planning and handling of immunosuppressed heart, liver, and kidney transplant patients. Special Care in Dentistry, 1996, 16, 242-246.	0.8	15
140	Randomized Trial of Fluconazole versus Nystatin for the Prophylaxis of Candida Infection following Liver Transplantation. Journal of Infectious Diseases, 1996, 174, 583-588.	4.0	163
141	Gadolinium chloride-induced Kupffer cell phagocytosis blockade promotes increased antibody (IgG1) response to orally administered ovalbumin in the rat. International Hepatology Communications, 1995, 3, 260-266.	0.7	1
142	Serum IgE levels in liver cirrhosis.. Contrasting results in alcoholic and non-alcoholic patients. Clinical and Experimental Allergy, 1994, 24, 540-548.	2.9	32
143	Influence of Kupffer cell phagocytosis blockade on the production of ovalbumin-specific IgE and IgG1 antibodies in an experimental model. Clinical and Experimental Allergy, 1993, 23, 15-20.	2.9	9
144	Role of the hepatic kupffer cells in the phagocytic splenic activity. Journal of Hepatology, 1991, 13, S126.	3.7	0

#	ARTICLE	IF	CITATIONS
145	Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. <i>Gastroenterology</i> , 1990, 98, 134-140.	1.3	112
146	Utility of hepatocellular transplantation into spleen as a temporary liver support in cirrhotic dogs. <i>Journal of Hepatology</i> , 1990, 10, P8.	3.7	0
147	EVIDENCE THAT TEMPORARY COMPLETE OCCLUSION OF SPLENIC VESSELS PREVENTS MASSIVE EMBOLIZATION AND SUDDEN DEATH ASSOCIATED WITH INTRASPLENIC HEPATOCELLULAR TRANSPLANTATION. <i>Transplantation</i> , 1989, 47, 449-450.	1.0	26
148	<i>Staphylococcus xylosum</i> from a patient with cardiac and hepatic transplants. <i>Clinical Microbiology Newsletter</i> , 1988, 10, 47-48.	0.7	0
149	DOES PREVIOUS ABDOMINAL SURGERY ALTER THE OUTCOME OF PEDIATRIC PATIENTS SUBJECTED TO ORTHOTOPIC LIVER TRANSPLANTATION?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1988, 7, 474.	1.8	0
150	Lipids and Lipoprotein Changes After Heart and Liver Transplantation in a Patient with Homozygous Familial Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 1988, 108, 204.	3.9	36
151	Does previous abdominal surgery alter the outcome of pediatric patients subjected to orthotopic liver transplantation?. <i>Gastroenterology</i> , 1986, 90, 853-857.	1.3	67
152	Adult liver transplantation: An analysis of the early causes of death in 40 consecutive cases. <i>Hepatology</i> , 1986, 6, 495-501.	7.3	136
153	Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. <i>Hepatology</i> , 1986, 6, 922-927.	7.3	179
154	Radiographic features of liver allograft rejection. <i>Gastrointestinal Radiology</i> , 1986, 11, 326-329.	0.4	11
155	TIME-RELATED EFFICACY OF LIVER CELL ISOGRAFTS IN FULMINANT HEPATIC FAILURE. <i>Transplantation</i> , 1984, 38, 23-24.	1.0	36
156	Effect of colistin on reduction of biliary flow induced by endotoxin of <i>E. coli</i> . <i>Digestive Diseases and Sciences</i> , 1982, 27, 875-879.	2.3	5
157	Plasma cell dyscrasia with polyneuritis and dermato-endocrine alterations. Report of a new case outside Japan. <i>Postgraduate Medical Journal</i> , 1980, 56, 427-430.	1.8	28
158	Medical workstation for the management of the transplantation unit of a hospital. , 0, , .		2